Objective: Our group has previously shown that a high percentage of ischemic wounds in patients with peripheral arterial disease heal with conservative therapy alone. However, some patients require delayed revascularization. Our goal was to evaluate wound healing and limb salvage among patients with ischemic wounds when revascularization was necessary after a failure of conservative therapy.
Veterans Affairs Loma Linda Healthcare System, Loma Linda, Calif Objective: Our group has previously shown that a high percentage of ischemic wounds in patients with peripheral arterial disease heal with conservative therapy alone. However, some patients require delayed revascularization. Our goal was to evaluate wound healing and limb salvage among patients with ischemic wounds when revascularization was necessary after a failure of conservative therapy.
Methods: Patients with peripheral arterial disease and tissue loss were prospectively enrolled into our Prevention of Amputation in Veterans Everywhere (PAVE) program. Limbs were stratified on the basis of perfusion evaluation and a validated pathway of care. Conservatively treated limbs that failed to demonstrate a positive wound trajectory underwent delayed revascularization. Rates of wound healing, recurrence, limb salvage, and survival were retrospectively compared of patients who underwent delayed vs immediate revascularization by univariate and multivariate analysis, controlling for Wound, Ischemia, and foot Infection (WIfI) classification.
Results [CI] , 0.6-3.1), recurrence (OR, 0.8; 95% CI, 0.3-1.8), limb salvage (OR, 0.7; 95% CI, 0.3-1.9), and survival (OR, 0.2; 95% CI, 0.6-2.5).
Conclusions: Patients who fail to respond to conservative therapy and undergo delayed revascularization achieve similar rates of wound healing and limb salvage as those undergoing immediate surgical intervention, independent of WIfI classification. A stratified approach to critical limb ischemia achieves acceptable clinical outcomes without introducing increased risk in patients in whom an initial attempt at conservative therapy fails.
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Endovascular Reconstruction Offers Noninferior Outcomes at Reduced Cost Compared With Surgical Bypass for TransAtlantic Inter-Society Consensus II D Aortoiliac Occlusive Disease
Joshua Gabel, Roger Tomihama, Ahmed Abou-zamzam Jr, Theodore Teruya, Christian Bianchi, Sharon Kiang. Loma Linda University, Loma Linda, Calif
Objective: The objective of this study was to compare the clinical outcomes and cost of endovascular reconstruction of occlusive and nearocclusive disease of the aortic bifurcation with surgical bypass.
Methods: Thirty-three consecutive patients with symptomatic TransAtlantic Inter-Society Consensus II D aortoiliac occlusive disease who underwent surgical bypass or endovascular reconstruction from 2012 to 2017 were retrospectively reviewed. Lesion characteristics, technical approach, survival, limb salvage, and patency were analyzed. Device, operating room, and length of stay costs were calculated on the basis of rates provided by the Department of Veterans Affairs and compared between treatment groups.
Results: Nineteen patients at prohibitive risk for open surgery underwent endovascular reconstruction; 13 underwent surgical bypass. Kissing stent technique was used in all patients for reconstruction of the aortic bifurcation. The endovascular group had decreased operative time (157 vs 245 minutes; P ¼ .004), blood loss (273 vs 763 mL; P ¼ .005), and perioperative complications (5% vs 31%; P ¼ .045) compared with surgical bypass. At mean follow-up of 2.8 years, endovascular reconstruction compared with surgical bypass demonstrated noninferior primary/primary assisted patency (85% vs 85%; P ¼ .98), limb salvage (100% vs 92%; P ¼ .76), and survival (90% vs 85%; P ¼ .65). Endovascular device costs were $4223 greater than for surgical bypass (P < .001), but endovascular reconstruction operating room cost was $3332 less than with surgical bypass (P ¼ .001). Length of stay cost was $13,580 less for patients undergoing endovascular reconstruction compared with surgery (P < .001) and led to an overall reduction of $11,706 in hospitalization costs in favor of endovascular reconstruction (P < .001).
Conclusions: Patients with occlusive and near-occlusive disease of the aortic bifurcation treated with endovascular reconstruction achieve noninferior outcomes of patency, limb salvage, and survival compared with surgical bypass at a mean 2.8 years. Decreased operative and length of stay costs associated with endovascular reconstruction produced an $11,706 cost advantage relative to surgical bypass.
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Multivessel Tibial Revascularization Does Not Improve Outcomes in Patients With Critical Limb Ischemia
Kedar S. Lavingia, Kenneth Tran, Nathan Itoga, Anahita Dua, Matthew Mell, Venita Chandra. Stanford, Stanford, Calif
Objective: Single-vessel vs multivessel revascularization for critical limb ischemia (CLI) remains controversial. The purpose of this study was to evaluate single vs multiple tibial vessel interventions in patients with multivessel tibial disease.
Methods: Using the Vascular Quality Initiative registry, we reviewed patients undergoing lower extremity endovascular interventions involving the tibial arteries. Patients with CLI were included if at least two tibial vessels were diseased and appropriate follow-up was documented. Primary outcomes were amputation, primary assisted patency, and amputationfree survival (AFS).
Results: After exclusions, a total of 761 patients with multivessel tibial disease and CLI were evaluated. Of these, 473 (62.1%) underwent single-vessel tibial intervention (group 1), whereas 288 (37.9%) underwent multivessel (two or more) intervention (group 2). Patients in group 2 were younger (69.1 vs 73.2 years; P < .001), with higher chance of smoking (29.5% vs 18.2%; P < .001). Prior ipsilateral amputation (19.2% vs 22.2%; P ¼ .22) or inflow procedures (3.1% vs 2.8%; P ¼ .29) were similar. Group 1 more commonly had concurrent femoral or popliteal inflow interventions (83.7% vs 78.1%; P ¼ .05). Multivessel runoff on completion was significantly greater for group 2 (99.9% vs 39.9%; P < .001). Mean follow-up was 337 6 62 days. No differences were observed between group 1 and group 2 for major amputation (9.0% and 7.6%; P ¼ .6), patency (89.7% vs 86.8%; P ¼ .45), or AFS (P ¼ .372; Fig) . In a multivariate Cox model, loss of patency was the only significant predictor of major amputation (hazard ratio, 5.36 [2.7-10.6]; P ¼ .01). A subgroup analysis of 355 (46.6%) patients with tissue loss data showed that tissue loss before intervention was not predictive of future major amputation.
Conclusions: In the Vascular Quality Initiative registry, patients with CLI and multivessel tibial disease did not appear to benefit in amputation, AFS, or primary assisted patency when undergoing multivessel tibial intervention compared with single tibial revascularization. Further studies are needed to determine when multivessel treatment is warranted for this population.
